Table 6.
Summary of the prevalence of EBV detection of investigated cases and controls.
| Study | EBV-Positive Cases/Total | EBV-Positive Controls/Total | Statistically Significant? Y/N (p-Value) |
|---|---|---|---|
| Charostad, 2021 [133] | 6/51 (12%) | 1/51 (1%) § | No (p = 0.0599) |
| Golrokh Mofrad, 2020 [134] | 4/59 (7%) | 0/59 (0%) # | No (p = 0.1186) |
| Mostafaei, 2020 [135] | 38/83 (46%) | 5/31 (16%) # | Yes (p = 0.004) |
| Dowran, 2019 [136] | 0/150 (0%) | 0/150 (0%) *,& | // |
| Sharifpour, 2019 [137] | 10/37 (27%) | 4/35 (18%) * | No (p = 0.09) |
| El-Naby, 2017 [139] | 10/42 (24%) | 6/42 (14%) * | No (p = 0.4) |
| Reza, 2015 [106] | 8/100 (8%) with Real time PCR 18/100 (18%) with Eber RNA |
0/100 (0%) § | Yes (p = 0.0068) |
| Richardson, 2015 [142] | 24/70 (34%) | 9/70 (12%) § | Yes (p = 0.0048) |
| Peng, 2014 [63] | 60/100 (60%) | 16/50 (32%) # | Yes (p = 0.0017) |
| Glenn, 2012 [17] | 34/50 (68%) with liquid PCR, 5/27 (19%) with IS-PCR |
14/40 (35%) ^ with liquid PCR, 6/18 (33%) ^ with IS-PCR |
Yes with liquid PCR (p = 0.0028) No with IS-PCR (p = 0.3040) |
| Zekri, 2012 [145] | 32/90 (35%) | 0/20 (0%) ^ | Yes (p = 0.0007) |
| Hachana, 2011 [146] | 33/123 (27%) | 0/123 (0%) § | Yes (p < 0.0001) |
| Kadivar, 2011 [147] | 0/100 (0%) | 0/42 (0%) # | // |
| Lorenzetti, 2010 [127] | 22/71 (31%) | 0/48 (0%) # | Yes (p < 0.0001) |
| Joshi, 2009 [149] | 28/58 (55%) | 0/30 (0%) # | Yes (p < 0.0001) |
| Fawzy, 2008 [150] | 10/40 (25%) | 0/10 (0%) & | No (p = 0.1791) |
* fibroadenomas, # unspecified benign lesions, § normal breast tissue from the same patient, ^ normal breast tissue from healthy patients, & fibrocystic disorder, //, data not available.